Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Haleon PLC ( (GB:HLN) ) just unveiled an update.
Haleon PLC announced the vesting of share awards to its Chief Financial Officer, Dawn Allen, under the company’s Share Value Plan and Performance Share Plan. These awards were part of her remuneration package to compensate for incentives forfeited from her previous employment. The vesting includes dividends and is subject to conditions such as continued employment and performance metrics. The shares are also subject to malus and clawback provisions, ensuring alignment with company performance and governance standards.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC’s overall stock score reflects strong financial performance and positive earnings call outlook. Despite some bearish technical indicators and valuation concerns, the company’s strategic initiatives in growth markets and its commitment to shareholder returns provide a positive long-term outlook. Challenges such as market headwinds and inventory adjustments are notable risks.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse product portfolio across six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon’s well-known brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, all of which are grounded in trusted science and innovation.
Average Trading Volume: 25,865,750
Technical Sentiment Signal: Hold
Current Market Cap: £33.74B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.